This gene overview is brought to you as part of Tempus’ goal to inform providers about our genomic testing panels and the genes included in our offerings. Through our robust de-identified database of clinical information coupled with molecular testing results, we are capable of providing unique insights into these gene alterations. Many of the gene alterations reported on our somatic and germline panels are often key inclusion criteria for clinical trials.
The ATM gene is a member of the PI3/PI4-kinase gene family. The ATM gene functions as a cell cycle checkpoint kinase, controlling the rate of cell growth and division. Additionally, it assists in the repair of damaged DNA. Loss of function mutations, copy number loss, and underexpression of ATM are associated with cancer progression.
ATM alterations in 10 most common cancers – Tempus database
FDA approved drugs for ATM mutated cancers
|Therapy||Tumor type (indication)||Biomarker|
|LYNPARZA® olaparib||Prostate cancer||HRR genes including ATM|
Some strategies in clinical development targeting ATM pathway
|Mechanism||Phase 1||Phase 2|
|PARP inhibitor||talazoparib (BMN 673) niraparib (MK-4827)|
|CHK1 inhibitor||prexasertib (LY2606368)|
|ATR Inhibitor||M4344 (VX-803)||M6620 (VX-970) ceralasertib (AZD6738)|
|Immunotherapy||nivolumab ipilimumab HX008 pembrolizumab|
View a more comprehensive list of clinical trials for patients with ATM mutated cancers. The Tempus TIME Trial ® Program brings the right clinical trial options directly to patients, for enrollment at your institution. Learn more